Celltrion, Mundipharma deal

Celltrion’s Celltrion Healthcare Hungary Kft subsidiary granted Mundipharma exclusive commercialization rights in the U.K., Germany, Italy, Belgium, Luxembourg and the Netherlands to Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). Remicade is a chimeric mAb against tumor necrosis factor (TNF) alpha. Celltrion and Mundipharma could not be reached for details. Merck, which markets Remicade in Europe, Russia and Turkey, reported $1.2 billion in sales of the product in the first six months of 2014. ...